Wound Management Technologies, Inc. Announces Filing of a 510K
The new product (patent pending) will combine the hydrolyzed collagen withthe healing properties of PSGAG (polysulfated glycosaminoglycan) and willinitially be available in gel form. Hydrolyzed collagen with PSGAG wound gelis an absorbent hydrolyzed collagen for the management of exudative wounds.When interacting with wound fluid hydrolyzed collagen with PSGAG wound gelimmediately begins to absorb wound exudates which may contain excess MMP'sthought to impair tissue regeneration. PSGAG has been shown in a porcinewound study to reduce the density of wound granulation tissue which in turnreduces resistance to epidermal migration.
Wound Care Innovations' patented advanced wound care hydrolyzed collagenproduct, CellerateRx(R), is FDA cleared for acute and chronic wounds whichinclude but are not limited to pressure ulcers (stage I-IV), traumatic wounds,diabetic ulcers, surgical wounds, venous stasis ulcers, ulcers due to arterialinsufficiency, superficial wounds, and 1st and 2nd degree burns. "We are veryexcited about the next generation product with our patented hydrolyzedcollagen," stated Cathy Bradshaw, President of Wound Care Innovations. "Webelieve that the addition of PSGAG will have an impact on the quality of woundgranulation tissue facilitating epidermal regeneration and will provideclinicians with yet another distinctive product for difficult wounds."
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (WNDM), with its corporateheadquarters in Fort Worth, Texas, markets and distributes wound care productsto the healthcare market under patented technology licensed to the Company.The Company is positioned and seeks to be a leading provider of wound careproducts. For more information on the Company please visit the Company'sWebsite at www.Celleraterx.com .
"Safe Harbor" Statement: Under The Private Securities Litigation ReformAct of 1995: The statements in the press release that relate to the company'sexpectations with regard to the future impact on the company's results fromnew products in development are "forward-looking statements," within themeaning of the Private Securities Litigation Reform Act of 1995. Since thisinformation may contain statements that involve risk and uncertainties and aresubject to change at any time, the company's actual results may differmaterially from expected results. This document may contain forward-lookingstatements concerning the Company's operations, current and future performanceand financial condition. These items involve risks and uncertainties such asproduct demand, market and customer acceptance, the effect of economicconditions, competition, pricing, the ability to consummate and integrateacquisitions, and other risks and uncertainties detailed in the Company's SECfilings. The Company undertakes no obligation to revise any of thesestatements to reflect the future circumstances or the occurrence ofunanticipated events.
Compensation Disclaimer: Capital Pros Network CPN has been compensated theequivalent of $50,000 from WNDM.OB. Certain oral statements made by managementfrom time to time and certain statements contained in press releases andperiodic reports issued by Capital Pros Network or WNDM.OB (the "Company"), aswell as those contained herein, that are not historical facts are "forward-looking statements" within the meaning of Section 21E of the Securities andExchange Act of 1934 and, because such statements involve risks anduncertainties, actual results may differ materially from those expressed orimplied by such forward-looking statements.
SOURCE Wound Management Technologies, Inc.
You May Also Like